Why TG Therapeutics Is Crashing Today

Shares of biotechnology company TG Therapeutics (NASDAQ: TGTX) are down 15.3% in Monday's late trading following a downgrade from investment bank Goldman Sachs.

TG Therapeutics' drug pipeline may not be as marketable as many investors believe it will be, according to Goldman Sachs analyst Corinne Jenkins. She downgraded the stock to a sell on Monday, citing limited revenue potential of its planned portfolio that's mostly being built around a single drug called umbralisib.

Image source: Getty Images.

Continue reading

Source Fool.com